Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Grade 2 IDH1-mutant Glioma”

10 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 10 results

Testing effectiveness (Phase 2)Looking for participantsNCT06161974
What this trial is testing

Study of Olutasidenib and Temozolomide in HGG

Who this might be right for
High Grade GliomaAstrocytomaAstrocytoma, Grade III+16 more
Rigel Pharmaceuticals 60
Large-scale testing (Phase 3)Not Yet RecruitingNCT07712757
What this trial is testing

Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma

Who this might be right for
Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 MutationAstrocytoma IDH Mutant Grade 2Oligodendroglioma+2 more
Nuvation Bio Inc. 140
Large-scale testing (Phase 3)Active Not RecruitingNCT06780930
What this trial is testing

Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation

Who this might be right for
Residual or Recurrent Grade 2 IDH Mutant Glioma
Servier 57
Testing effectiveness (Phase 2)Active Not RecruitingNCT03212274
What this trial is testing

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Who this might be right for
Advanced Malignant Solid NeoplasmGlioblastomaRecurrent Cholangiocarcinoma+4 more
National Cancer Institute (NCI) 89
Testing effectiveness (Phase 2)Active Not RecruitingNCT04458272
What this trial is testing

DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma

Who this might be right for
WHO Grade II Glioma
Daiichi Sankyo Co., Ltd. 25
Not applicableActive Not RecruitingNCT06969352
What this trial is testing

A Multicentre, Retrospective-prospective Real-world Study: to Evaluate the Effectiveness and Safety of Vorasidenib in Patients With Isocitrate Dehydrogenase IDH1/2 Mutant Grade 2 Astrocytoma or Oligodendroglioma (VICTORIA Study)

Who this might be right for
Gliomas
Servier (Tianjin) Pharmaceutical Co. LTD. 62
Large-scale testing (Phase 3)Looking for participantsNCT05303519
What this trial is testing

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

Who this might be right for
GliomaAstrocytoma, Grade IVIDH1-mutant Glioma+5 more
Nuvation Bio Inc. 365
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07703436
What this trial is testing

Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease

Who this might be right for
Grade 2 IDH1-mutant GliomaGrade 3 IDH1-mutant GliomaGlioma+5 more
Nuvation Bio Inc. 40
Testing effectiveness (Phase 2)WithdrawnNCT02977689
What this trial is testing

Trial of IDH305 in IDH1 Mutant Grade II or III Glioma

Who this might be right for
Glioma
NYU Langone Health
Early research (Phase 1)Active Not RecruitingNCT03749187
What this trial is testing

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

Who this might be right for
GlioblastomaIDH1 Gene MutationIDH2 Gene Mutation+7 more
University of California, San Francisco 78